Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: Retrospective analysis of six cases

Michitaka Nakano, Hitoshi Kusaba, Akitaka Makiyama, hiroshi ariyama, Shuji Arita, Hisanobu Oda, Taito Esaki, Kotoe Takayoshi, Keita Uchino, Shingo Tamura, Hozumi Kumagai, Eiji Iwama, Tsuyoshi Shirakawa, Kenji Mitsugi, Shigeo Takaishi, Koichi Akashi, Eishi Baba

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Malignant peritoneal mesothelioma (PM) is an extremely rare disease. Pemetrexed and platinum have been used for advanced PM following malignant pleural mesothelioma (PLM). Because PM differs considerably from PLM in clinical features, the efficacy and safety of these therapies have yet to be established. Patients and Methods: Six Japanese patients with PM who had been treated with pemetrexed-based chemotherapy in four Institutions were retrospectively identified. Treatment response, progression-free survival, and overall survival were examined. Toxicities of therapy were also evaluated. Results: Three patients with mild ascites achieved clinical benefits (one with partial response and two with stable disease). Treatments with reduced cisplatin or carboplatin for patients with massive ascites were safely performed. Median PFS and OS were 7.2 and 13.1 months, respectively. Grade 3 hematological toxicities appeared in two patients with massive ascites. Conclusion: Selection of chemotherapy based on the patient's condition, such as ascites, might be important for advanced PM.

Original languageEnglish
Pages (from-to)215-220
Number of pages6
JournalAnticancer Research
Volume34
Issue number1
Publication statusPublished - Jan 1 2014

Fingerprint

Pemetrexed
Platinum
Mesothelioma
Ascites
Drug Therapy
Carboplatin
Therapeutics
Rare Diseases
Cisplatin
Disease-Free Survival
Malignant Mesothelioma
Safety
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma : Retrospective analysis of six cases. / Nakano, Michitaka; Kusaba, Hitoshi; Makiyama, Akitaka; ariyama, hiroshi; Arita, Shuji; Oda, Hisanobu; Esaki, Taito; Takayoshi, Kotoe; Uchino, Keita; Tamura, Shingo; Kumagai, Hozumi; Iwama, Eiji; Shirakawa, Tsuyoshi; Mitsugi, Kenji; Takaishi, Shigeo; Akashi, Koichi; Baba, Eishi.

In: Anticancer Research, Vol. 34, No. 1, 01.01.2014, p. 215-220.

Research output: Contribution to journalArticle

Nakano, M, Kusaba, H, Makiyama, A, ariyama, H, Arita, S, Oda, H, Esaki, T, Takayoshi, K, Uchino, K, Tamura, S, Kumagai, H, Iwama, E, Shirakawa, T, Mitsugi, K, Takaishi, S, Akashi, K & Baba, E 2014, 'Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: Retrospective analysis of six cases', Anticancer Research, vol. 34, no. 1, pp. 215-220.
Nakano, Michitaka ; Kusaba, Hitoshi ; Makiyama, Akitaka ; ariyama, hiroshi ; Arita, Shuji ; Oda, Hisanobu ; Esaki, Taito ; Takayoshi, Kotoe ; Uchino, Keita ; Tamura, Shingo ; Kumagai, Hozumi ; Iwama, Eiji ; Shirakawa, Tsuyoshi ; Mitsugi, Kenji ; Takaishi, Shigeo ; Akashi, Koichi ; Baba, Eishi. / Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma : Retrospective analysis of six cases. In: Anticancer Research. 2014 ; Vol. 34, No. 1. pp. 215-220.
@article{98288ad9dcf94c44b5ae6d2045b57e78,
title = "Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: Retrospective analysis of six cases",
abstract = "Background: Malignant peritoneal mesothelioma (PM) is an extremely rare disease. Pemetrexed and platinum have been used for advanced PM following malignant pleural mesothelioma (PLM). Because PM differs considerably from PLM in clinical features, the efficacy and safety of these therapies have yet to be established. Patients and Methods: Six Japanese patients with PM who had been treated with pemetrexed-based chemotherapy in four Institutions were retrospectively identified. Treatment response, progression-free survival, and overall survival were examined. Toxicities of therapy were also evaluated. Results: Three patients with mild ascites achieved clinical benefits (one with partial response and two with stable disease). Treatments with reduced cisplatin or carboplatin for patients with massive ascites were safely performed. Median PFS and OS were 7.2 and 13.1 months, respectively. Grade 3 hematological toxicities appeared in two patients with massive ascites. Conclusion: Selection of chemotherapy based on the patient's condition, such as ascites, might be important for advanced PM.",
author = "Michitaka Nakano and Hitoshi Kusaba and Akitaka Makiyama and hiroshi ariyama and Shuji Arita and Hisanobu Oda and Taito Esaki and Kotoe Takayoshi and Keita Uchino and Shingo Tamura and Hozumi Kumagai and Eiji Iwama and Tsuyoshi Shirakawa and Kenji Mitsugi and Shigeo Takaishi and Koichi Akashi and Eishi Baba",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "215--220",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma

T2 - Retrospective analysis of six cases

AU - Nakano, Michitaka

AU - Kusaba, Hitoshi

AU - Makiyama, Akitaka

AU - ariyama, hiroshi

AU - Arita, Shuji

AU - Oda, Hisanobu

AU - Esaki, Taito

AU - Takayoshi, Kotoe

AU - Uchino, Keita

AU - Tamura, Shingo

AU - Kumagai, Hozumi

AU - Iwama, Eiji

AU - Shirakawa, Tsuyoshi

AU - Mitsugi, Kenji

AU - Takaishi, Shigeo

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Malignant peritoneal mesothelioma (PM) is an extremely rare disease. Pemetrexed and platinum have been used for advanced PM following malignant pleural mesothelioma (PLM). Because PM differs considerably from PLM in clinical features, the efficacy and safety of these therapies have yet to be established. Patients and Methods: Six Japanese patients with PM who had been treated with pemetrexed-based chemotherapy in four Institutions were retrospectively identified. Treatment response, progression-free survival, and overall survival were examined. Toxicities of therapy were also evaluated. Results: Three patients with mild ascites achieved clinical benefits (one with partial response and two with stable disease). Treatments with reduced cisplatin or carboplatin for patients with massive ascites were safely performed. Median PFS and OS were 7.2 and 13.1 months, respectively. Grade 3 hematological toxicities appeared in two patients with massive ascites. Conclusion: Selection of chemotherapy based on the patient's condition, such as ascites, might be important for advanced PM.

AB - Background: Malignant peritoneal mesothelioma (PM) is an extremely rare disease. Pemetrexed and platinum have been used for advanced PM following malignant pleural mesothelioma (PLM). Because PM differs considerably from PLM in clinical features, the efficacy and safety of these therapies have yet to be established. Patients and Methods: Six Japanese patients with PM who had been treated with pemetrexed-based chemotherapy in four Institutions were retrospectively identified. Treatment response, progression-free survival, and overall survival were examined. Toxicities of therapy were also evaluated. Results: Three patients with mild ascites achieved clinical benefits (one with partial response and two with stable disease). Treatments with reduced cisplatin or carboplatin for patients with massive ascites were safely performed. Median PFS and OS were 7.2 and 13.1 months, respectively. Grade 3 hematological toxicities appeared in two patients with massive ascites. Conclusion: Selection of chemotherapy based on the patient's condition, such as ascites, might be important for advanced PM.

UR - http://www.scopus.com/inward/record.url?scp=84897058906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897058906&partnerID=8YFLogxK

M3 - Article

C2 - 24403465

AN - SCOPUS:84897058906

VL - 34

SP - 215

EP - 220

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -